Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1021-1030
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Table 2 Relative dose intensity of the capecitabine or S-1 for advanced gemcitabine refractory pancreatic cancer
| Capecitabine (n = 41) | S-1 (n = 40) | P value | |
| Duration of treatment, months | |||
| Median | 1.7 | 2.0 | 0.120 |
| Range | 0.7-6.9 | 0.8-6.2 | |
| Dose intensity | |||
| Median | 0.92 | 1.00 | 0.986 |
| Range | 0.70-1.00 | 0.50-1.00 | |
- Citation: Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030
- URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1021